Pyxis Oncology, Inc. (PYXS) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-0.4%

$1.68

vs $1.69 price

Levered DCF

$0.37

After debt service

Piotroski score

2 / 9

Weak

Altman Z-score

-15.92

Distress zone

Rating

C-

Overall 1 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
P/E	-0.9×	-1.18×	-0.97×	-0.38×	-4.34×	-35.68×	-169.88×
P/B	1.34×	0.76×	0.57×	0.28×	1.35×	-28.95×	-157.58×
P/S	5.16×	5.65×	0×	0×	0×	0×	0×
EV / EBITDA	-1.01×	-1.4×	-1.16×	0.97×	-1.05×	-36.05×	-156.28×
Gross margin	82.8%	97.1%	0.0%	0.0%	0.0%	0.0%	0.0%
Operating margin	-609.2%	-554.1%	0.0%	0.0%	0.0%	0.0%	0.0%
Net margin	-574.5%	-478.9%	0.0%	0.0%	0.0%	0.0%	0.0%
Current ratio	3.41×	7.49×	4.84×	5.9×	14.9×	2.2×	26.88×
Debt / equity	0.35×	0.17×	0.17×	0.12×	0×	-0.05×	-0.01×
Interest coverage	0×	0×	0×	0×	0×	0×	0×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Return on equity	-149.1%	-64.0%	-58.7%	-75.1%	-29.1%	82.0%	96.5%
Return on invested capital	-117.1%	-61.7%	-55.1%	-68.7%	-26.7%	-182.2%	-15.1%
Return on assets	-87.0%	-49.2%	-42.5%	-57.1%	-27.1%	-126.4%	-14.0%
Free cash flow yield	-88.9%	-63.5%	-107.8%	-216.3%	-10.1%	-2.6%	-0.5%
Earnings yield	-111.4%	-84.8%	-102.7%	-272.7%	-21.5%	-2.8%	-0.6%
Enterprise value	$74.7M	$91.9M	$83.5M	-$116.1M	$78.9M	$445.6M	$433.2M
Net debt / EBITDA	-0.04×	-0.01×	-0.16×	1.34×	3.64×	0.59×	7.1×
Cash conversion cycle (days)	-1,645	-3,734	0	0	0	-885	0